Digital technology is fast becoming a gateway to better measurements and assessments of neurological function. It has given rise to new digital therapeutics that have the potential to improve outcomes, reduce costs, and help shift the delivery of care outside traditional settings. Pharma is an active partner with these firms, but so far medtech is standing pat.
Neuro-focused prescription digital health companies are taking aim at a range of diseases from psychiatric/mental health disorders to neurodegenerative diseases and even chronic diseases. More and more, the apps and software they are developing are being cleared by the FDA’s Center for Devices and Radiological Health as medical devices.